PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDalbavancin
Dalvance, Xydalba(dalbavancin)
Dalvance, Xydalba (dalbavancin) is an unknown pharmaceutical. Dalbavancin was first approved as Dalvance on 2014-05-23. It is used to treat bacterial infections, infectious skin diseases, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial skin diseases and soft tissue infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Dalvance
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dalbavancin hydrochloride
Tradename
Company
Number
Date
Products
DALVANCEAbbVieN-021883 RX2014-05-23
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
dalbavancinNew Drug Application2014-06-05
dalvanceNew Drug Application2025-01-13
Agency Specific
FDA
EMA
Expiration
Code
DALBAVANCIN HYDROCHLORIDE, DALVANCE, ABBVIE
2024-07-22NPP
2024-05-23GAIN
2019-05-23NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Dalbavancin Hydrochloride, Dalvance, Abbvie
69001752028-05-23U-3499
ATC Codes
J: Antiinfectives for systemic use
J01: Antibacterials for systemic use
J01X: Other antibacterials in atc
J01XA: Glycopeptide antibacterials
J01XA04: Dalbavancin
HCPCS
Code
Description
J0875
Injection, dalbavancin, 5 mg
Clinical
Clinical Trials
3882 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients11753328152
Breast neoplasmsD001943EFO_0003869C50384917230120
Diabetes mellitusD003920EFO_0000400E08-E1315114174286
SyndromeD013577826753980
ObesityD009765EFO_0001073E66.988724671
LeukemiaD007938C95353271466
Type 2 diabetes mellitusD003924EFO_0001360E111387142765
StrokeD020521EFO_0000712I63.937824260
LymphomaD008223C85.9332862157
InfectionsD007239EFO_000054410121591353
Show 321 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8013263931197
Non-small-cell lung carcinomaD00228939458480
CarcinomaD002277C80.0343210871
Lung neoplasmsD008175C34.90263241062
Colorectal neoplasmsD015179212791661
Myeloid leukemia acuteD015470C92.020256445
Myeloid leukemiaD007951C9218246242
MelanomaD00854523191439
Ovarian neoplasmsD010051EFO_0003893C5618156438
Liver neoplasmsD008113EFO_1001513C22.015156333
Show 283 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell carcinoma of head and neckD0000771951214224
Head and neck neoplasmsD006258910522
GlioblastomaD005909EFO_0000515711117
Weight lossD015431121417
Spinal cord injuriesD013119EFO_1001919231215
Renal cell carcinomaD002292EFO_000037677214
Small cell lung carcinomaD05575288213
EmergenciesD00463011213
Body weightD001835EFO_000433821012
PruritusD011537L2911011
Show 287 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnxietyD001007EFO_0005230F41.112122
Urinary incontinenceD014549R32189
Psychological burnoutD000077062Z73.0189
PharmacokineticsD01059977
NeuroblastomaD009447EFO_0000621426
Pulmonary arterial hypertensionD000081029336
MalnutritionD044342EFO_0008572E40-E46156
Gastroesophageal refluxD005764EFO_0003948K21156
Professional burnoutD002055134
Patient participationD010358123
Show 120 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Trigger finger disorderD052582M65.32424
Cerebral palsyD002547G801111
ParalysisD0102431010
SleepD012890GO_003043188
Autism spectrum disorderD000067877F84.088
MyopiaD009216EFO_0003927H52.188
Child developmentD00265788
Gingival recessionD005889K06.088
Acute painD059787R5277
Dental implantsD01592177
Show 603 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDalbavancin
INNdalbavancin
Description
Dalbavancin is a semisynthetic glycopeptide used for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA. It has a role as an antibacterial drug and an antimicrobial agent. It is a carbohydrate acid derivative, a monosaccharide derivative, a glycopeptide and a semisynthetic derivative.
Classification
Small molecule
Drug classvancomycin-related compounds
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN[C@H]1C(=O)N[C@@H]2Cc3ccc(cc3)Oc3cc4cc(c3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@@H](C(=O)NCCCN(C)C)NC3=O
Identifiers
PDB
CAS-ID171500-79-1
RxCUI
ChEMBL IDCHEMBL3301669
ChEBI ID82721
PubChem CID16134627
DrugBankDB06219
UNII ID808UI9MS5K (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
Dalvance Allergan
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Dalvance Warner Chilcott
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,220 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,049 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use